$1.24 billion is the projected 2026 size of the peptide coupling reagents market, with revenue forecast to climb to $2.91 billion by 2036 at an 8.9% CAGR.
8.9% growth is tied to peptide API scale-up, rising regulated synthesis needs and stronger buyer demand for documented, process-critical reagents rather than basic catalog chemicals.
38.7% of the 2026 market is expected to come from uronium/guanidinium reagents, while solid-phase peptide synthesis should account for 64.3% as automated lines need repeatable activation chemistry.
India leads country growth with a 10.0% CAGR through 2036, ahead of China at 9.6% and the United States at 9.2%, reflecting expanding peptide manufacturing capacity in Asia and sustained research intensity elsewhere.
Safety and compliance are also reshaping supplier competition, as HOBt-related hazard concerns and residual-solvent scrutiny push buyers toward safer alternatives with stronger documentation and traceability.